Exploiting Chemical Diversity for Drug Discovery (eBook, PDF)
Redaktion: Bartlett, Paul A; Entzeroth, Michael
Alle Infos zum eBook verschenken
Exploiting Chemical Diversity for Drug Discovery (eBook, PDF)
Redaktion: Bartlett, Paul A; Entzeroth, Michael
- Format: PDF
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
Hier können Sie sich einloggen
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
Conceptual and technological advances in chemistry and biology have transformed the drug discovery process. Evolutionary pressure among the diverse scientific and engineering disciplines that contribute to the identification of biologically active compounds has resulted in synergistic improvements at every step in the process. Exploiting Chemical Diversity for Drug Discovery encompasses the many components of this transformation and presents the current state-of-the-art of this critical endeavour. From the theoretical and operational considerations in generating a collection of compounds to…mehr
- Geräte: PC
- ohne Kopierschutz
- eBook Hilfe
- Größe: 5.92MB
- Epigenetics for Drug Discovery (eBook, PDF)211,95 €
- Orphan Drugs and Rare Diseases (eBook, PDF)206,95 €
- Allosterism in Drug Discovery (eBook, PDF)211,95 €
- Kinase Drug Discovery (eBook, PDF)198,95 €
- Annual Reports in Medicinal Chemistry (eBook, PDF)118,95 €
- Cytochromes P450 (eBook, PDF)171,95 €
- Peptide-based Drug Discovery (eBook, PDF)211,95 €
-
-
-
Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, D ausgeliefert werden.
- Produktdetails
- Verlag: RSC
- Seitenzahl: 444
- Erscheinungstermin: 31. Oktober 2007
- Englisch
- ISBN-13: 9781847552556
- Artikelnr.: 44761852
- Verlag: RSC
- Seitenzahl: 444
- Erscheinungstermin: 31. Oktober 2007
- Englisch
- ISBN-13: 9781847552556
- Artikelnr.: 44761852
- Herstellerkennzeichnung Die Herstellerinformationen sind derzeit nicht verfügbar.
Chapter 1: The Use of Polymer-assisted Solution-phase Synthesis and Automation for the High-throughput Preparation of Biologically Active Compounds
1: Introduction
2: PASP Synthesis Approaches to Biologically Active Compounds
3: Automated PASP Synthesis of Biologically Active Molecules
4: Flow Chemistry and Automation in the Synthesis of Drug-Like Molecules
5: Conclusion
6: References
Chapter 2: Accelerated Chemistry: Microwave, Sonochemical, and Fluorous Phase Techniques
1: Introduction
2: Microwave Enhanced Chemistry
3: Sonochemistry as a Means to Accelerate Synthesis
4: Fluorous Phase Techniques
5: Conclusion
6: References
Part Two: Conceptual Advances in Synthesis
Chapter 3: Biosynthesis of "Unnatural" Natural Products
1: Introduction
2: Type I Polyketide Synthases
3: Type II Polyketide Synthases
4: Type III Polyketide Synthase
5: Conclusions
6: Acknowledgements
7: References
Chapter 4: Vombinatorial Synthetic Design: the Balance of Novelty and Familiarity
1: Biological Macromolecules - Strength in Numbers
2: Oligomer Synthesis - Improving on Mother Nature
3: Random, Discovery, or Prospecting Libraries - the Quest for the Universal Scaffold
4: Privileged Scaffolds - Look Where the Light is Brightest
5: The Decoration or Synthesis of Novel Scaffolds - Aid for the Underprivileged
6: Target Class Libraries - Diversity with a Purpose
7: Peptide and Nucleotide Libraries Redux
8: Lead Discovery or Drug Discovery - Size Does Matter
9: Natural Product Scaffolds for Combinatorial Chemistry - Why Re-invent the Wheel?
10: From Natural Products to Natural Product-like Libraries - Hubris or Progress?
11: Lead Discovery and Combinatorial Chemistry - What Have we Learned?
12: References
Chapter 5: Compound Collections: Acquisition, Annotation, and Access
1: Introduction
2: Commercial Offerings
3: Companies Providing Non-proprietry, Non-parallel Synthesised Libraries (Shared-pool/"Collected Collections")
4: Companies Providing In-house Designed, Parallel Synthesised Libraries
5: Compound Selection and Database Filtering
6: Substructure Similarity/Dissimilarity
7: Pharmacophore Analysis
8: Lipinski Rule-of-Five (LRoF)
9: Topological Polar Surface Area (tPSA) and Blood-Brain-Barrier Permeability (LogBB)
10: Solubility
11: Examples of the Use of Chemical Annotation and Pharmacophore based lead-hopping
12: Compound Acquisition
13: References
Chapter 6: Chemical Diversity: Definition and Quantification
1: Introduction
2: Diversity Metrics
3: Molecular Description
4: Dimensionality Reduction
5: Subset Selection and Classification
6: Conclusion
7: Abbreviations
8: References
Part Three: Mining: Turning a Hit into a Lead
Chapter 7: Focused Libraries: the Evolution in Strategy from Large Diversity Libraries to the Focused Library Approach
1: Introduction
2: A Synergistic, Multidisciplinary Approach to Library Conception
3: Library Design Concepts
4: Focused libraries
5: Summary
6: References
Chapter 8: Translating Peptides into Small Molecules
1: Peptides as Drugs: The Good, the Bad and the Ugly
2: Origin of Biologically Active Peptides
3: General Strategy for Translating Peptides into Small Molecules
4: Tailoring Peptide Sequences for Their Translation into Small Molecules
5: Transformation of peptide Ligands into Small Molecules Using Computational Approaches
6: References
Part Four: Operational Developments in Screening
Chapter 9: High Density Plates, Microarrays, Microfluidics
1: Functional High-density Well Plates for High-throughput Assays
2: Parallel Liquid Handling of Low-volume Samples
3: Microarray Assays on Chips
4: Prospects for Multi-Parameter Assays
5: References
Chapter 10: Fluorescence Technologies for the Investigation of Chemical Libraries
1: Introduction
2: Dissociation Enhanced Lanthanide Fluoroimmunoassay (DELFIA)
3: Enzyme Fragment Complementation (EFC)
4: Fluorescence Polarization (FP)
5: Fluorescence Correlation Spectroscopy (FCS)
6: Amplified Luminescent Proximity Homogeneous Assay (Alphascreen)
7: Fluorescence Resonance Energy Transfer (FRET)
8: Bioluminescence Resonance Energy Transfer (BRET)
9: Homogeneous Time Resolved Fluorescence (HTRF)
10: Conclusion
11: References
Chapter 11: The Use of Genetically Engineered Cell-based Assays in in-vitro Drug Discovery
1: Introduction
2: Genetic Engineering for Cell-based Assays
3: Reporter-based Assays
4: Assays to Measure Intracellular Calcium
5: Assays to Monitor Protein-Protein Interactions
6: Conclusions and Outlook
7: References
Chapter 12: NMR Based Screening, a Powerful Tool in Fragment-based Drug Discovery
1: Introduction
2: NMR Screening: General Aspects
3: Ligand- vs Traget-detected Methods
4: Incorporation of NMR into the Drug Discovery Process
5: Representative Case Studies
6: Conclusion
7: References
Chapter 13: Screening Chemical Microarrays: Methods and Applications
1: Introduction
2: Screening of Chemical Microarrays
3: Applications of Chemical Microarrays
4: Conclusion
5: References
Part Five: Conceptual Advances in Lead Evaluation
Chapter 14: Screen/Counter-screen: Early Assessment of Selectivity
1: Introduction
2: Approaches Used for Selection of Drug Candidates
3: Summary
4: References
Chapter 15: Concepts for in-vitro Profiling - Drug Activity, Selectivity and Liability
1: Introduction
2: Physico Chemical Parameters
3: Permeability
4: Metabolism
5: Protein Binding
6: Toxicity
7: Investigation of Compound Selectivity
8: Conclusion and Outlook
9: Reference
Chapter 16: In silico Surrogates for in vivo Properties: Profiling for ADME and Toxicological Behavior
1: In silico Surrogates for in vivo Properties
2: Estimation of Biopharmaceutical Properties
3: Estimation of Pharmacokinetic Properties
4: Estimation of Toxicological Properties
5: Integration of Surrogate Data and Estimations with Physiological Simulation
6: References
Chapter 17: Use of High Content Screening in Chemical Optimization
1: Introduction
2: HCS Systems
3: Examples Show the Power of HCS
4: Summary
Chapter 1: The Use of Polymer-assisted Solution-phase Synthesis and Automation for the High-throughput Preparation of Biologically Active Compounds
1: Introduction
2: PASP Synthesis Approaches to Biologically Active Compounds
3: Automated PASP Synthesis of Biologically Active Molecules
4: Flow Chemistry and Automation in the Synthesis of Drug-Like Molecules
5: Conclusion
6: References
Chapter 2: Accelerated Chemistry: Microwave, Sonochemical, and Fluorous Phase Techniques
1: Introduction
2: Microwave Enhanced Chemistry
3: Sonochemistry as a Means to Accelerate Synthesis
4: Fluorous Phase Techniques
5: Conclusion
6: References
Part Two: Conceptual Advances in Synthesis
Chapter 3: Biosynthesis of "Unnatural" Natural Products
1: Introduction
2: Type I Polyketide Synthases
3: Type II Polyketide Synthases
4: Type III Polyketide Synthase
5: Conclusions
6: Acknowledgements
7: References
Chapter 4: Vombinatorial Synthetic Design: the Balance of Novelty and Familiarity
1: Biological Macromolecules - Strength in Numbers
2: Oligomer Synthesis - Improving on Mother Nature
3: Random, Discovery, or Prospecting Libraries - the Quest for the Universal Scaffold
4: Privileged Scaffolds - Look Where the Light is Brightest
5: The Decoration or Synthesis of Novel Scaffolds - Aid for the Underprivileged
6: Target Class Libraries - Diversity with a Purpose
7: Peptide and Nucleotide Libraries Redux
8: Lead Discovery or Drug Discovery - Size Does Matter
9: Natural Product Scaffolds for Combinatorial Chemistry - Why Re-invent the Wheel?
10: From Natural Products to Natural Product-like Libraries - Hubris or Progress?
11: Lead Discovery and Combinatorial Chemistry - What Have we Learned?
12: References
Chapter 5: Compound Collections: Acquisition, Annotation, and Access
1: Introduction
2: Commercial Offerings
3: Companies Providing Non-proprietry, Non-parallel Synthesised Libraries (Shared-pool/"Collected Collections")
4: Companies Providing In-house Designed, Parallel Synthesised Libraries
5: Compound Selection and Database Filtering
6: Substructure Similarity/Dissimilarity
7: Pharmacophore Analysis
8: Lipinski Rule-of-Five (LRoF)
9: Topological Polar Surface Area (tPSA) and Blood-Brain-Barrier Permeability (LogBB)
10: Solubility
11: Examples of the Use of Chemical Annotation and Pharmacophore based lead-hopping
12: Compound Acquisition
13: References
Chapter 6: Chemical Diversity: Definition and Quantification
1: Introduction
2: Diversity Metrics
3: Molecular Description
4: Dimensionality Reduction
5: Subset Selection and Classification
6: Conclusion
7: Abbreviations
8: References
Part Three: Mining: Turning a Hit into a Lead
Chapter 7: Focused Libraries: the Evolution in Strategy from Large Diversity Libraries to the Focused Library Approach
1: Introduction
2: A Synergistic, Multidisciplinary Approach to Library Conception
3: Library Design Concepts
4: Focused libraries
5: Summary
6: References
Chapter 8: Translating Peptides into Small Molecules
1: Peptides as Drugs: The Good, the Bad and the Ugly
2: Origin of Biologically Active Peptides
3: General Strategy for Translating Peptides into Small Molecules
4: Tailoring Peptide Sequences for Their Translation into Small Molecules
5: Transformation of peptide Ligands into Small Molecules Using Computational Approaches
6: References
Part Four: Operational Developments in Screening
Chapter 9: High Density Plates, Microarrays, Microfluidics
1: Functional High-density Well Plates for High-throughput Assays
2: Parallel Liquid Handling of Low-volume Samples
3: Microarray Assays on Chips
4: Prospects for Multi-Parameter Assays
5: References
Chapter 10: Fluorescence Technologies for the Investigation of Chemical Libraries
1: Introduction
2: Dissociation Enhanced Lanthanide Fluoroimmunoassay (DELFIA)
3: Enzyme Fragment Complementation (EFC)
4: Fluorescence Polarization (FP)
5: Fluorescence Correlation Spectroscopy (FCS)
6: Amplified Luminescent Proximity Homogeneous Assay (Alphascreen)
7: Fluorescence Resonance Energy Transfer (FRET)
8: Bioluminescence Resonance Energy Transfer (BRET)
9: Homogeneous Time Resolved Fluorescence (HTRF)
10: Conclusion
11: References
Chapter 11: The Use of Genetically Engineered Cell-based Assays in in-vitro Drug Discovery
1: Introduction
2: Genetic Engineering for Cell-based Assays
3: Reporter-based Assays
4: Assays to Measure Intracellular Calcium
5: Assays to Monitor Protein-Protein Interactions
6: Conclusions and Outlook
7: References
Chapter 12: NMR Based Screening, a Powerful Tool in Fragment-based Drug Discovery
1: Introduction
2: NMR Screening: General Aspects
3: Ligand- vs Traget-detected Methods
4: Incorporation of NMR into the Drug Discovery Process
5: Representative Case Studies
6: Conclusion
7: References
Chapter 13: Screening Chemical Microarrays: Methods and Applications
1: Introduction
2: Screening of Chemical Microarrays
3: Applications of Chemical Microarrays
4: Conclusion
5: References
Part Five: Conceptual Advances in Lead Evaluation
Chapter 14: Screen/Counter-screen: Early Assessment of Selectivity
1: Introduction
2: Approaches Used for Selection of Drug Candidates
3: Summary
4: References
Chapter 15: Concepts for in-vitro Profiling - Drug Activity, Selectivity and Liability
1: Introduction
2: Physico Chemical Parameters
3: Permeability
4: Metabolism
5: Protein Binding
6: Toxicity
7: Investigation of Compound Selectivity
8: Conclusion and Outlook
9: Reference
Chapter 16: In silico Surrogates for in vivo Properties: Profiling for ADME and Toxicological Behavior
1: In silico Surrogates for in vivo Properties
2: Estimation of Biopharmaceutical Properties
3: Estimation of Pharmacokinetic Properties
4: Estimation of Toxicological Properties
5: Integration of Surrogate Data and Estimations with Physiological Simulation
6: References
Chapter 17: Use of High Content Screening in Chemical Optimization
1: Introduction
2: HCS Systems
3: Examples Show the Power of HCS
4: Summary